State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA
Relay Therapeutics
Applies structural biology and computational chemistry to target protein motion.
What they do
Relay Therapeutics integrates experimental and computational technologies to analyze protein motion. Their platform enables the design of precision medicines that target complex protein conformations, delivering therapeutic solutions to oncology and genetic disease patients.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Structure based design
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Cambridge, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $520M raised
Notable investors: SoftBank Vision Fund, Third Rock Ventures, T. Rowe Price, Fidelity Management.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA